Form 4: Relay Therapeutics Officer Sells Shares to Cover Tax Obligations

Peter Rahmer, Chief Corporate Development Officer of Relay Therapeutics, sold 247 shares of common stock on March 27, 2025, to cover income tax withholding obligations upon the vesting of restricted stock units.

Summary

• On March 27, 2025, Peter Rahmer, Chief Corporate Development Officer of Relay Therapeutics, sold 247 shares of common stock at a price of $2.84 per share.
• The sale was executed to cover income tax withholding obligations related to the vesting of 992 restricted stock units (RSUs) on March 26, 2025.
• Following the transaction, Rahmer beneficially owns 402,184 shares of Relay Therapeutics, which includes 252,612 shares underlying RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the transaction is a routine sale of shares to cover tax obligations. It doesn't indicate a significant positive or negative outlook for the company.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. This filing indicates a sale of shares to cover tax obligations, which is a common practice.

Stakeholder Impact

• The sale of shares by an officer could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.

Key Dates

Keywords

Form 4, Relay Therapeutics, RLAY, Peter Rahmer, Stock Sale, Restricted Stock Units, RSUs, Beneficial Ownership, Officer Transaction